Lund, Sweden, June 12, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), is pleased to welcome investors and analysts to a Capital Markets Day on June 25, 2026. The Capital Markets Day will be held at The St. Regis Hotel, Two East 55th Street, at Fifth Avenue, New York, and will be broadcast live online. […]
Collaboration will evaluate Scenic’s first-in-class PLA2G15 inhibitor program in Parkinson’s disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving lysosomal health as a therapeutic angle for Parkinson’s disease Amsterdam, The Netherlands — 11 June, 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose function‑first genomics engine has […]
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and Organon Oriva’s lead asset, ORV-362 – a non-hormonal, disease-modifying, first-in-class therapy for endometriosis – is already […]
Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication · First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations · Second poster demonstrates the potential for POLB […]
Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]
